Patent foramen ovale (PFO) closure reduced the risk for recurrent ischemic stroke in most young and middle-aged adults with cryptogenic stroke but increased the risk for atrial fibrillation (AF) in a ...

A retrospective comparison of six patent foramen ovale (PFO) closure devices used in the United States over 18 years shows a trade-off between effectiveness and arrhythmia. Specifically, the ...

Long-term follow-up of patients who underwent patent foramen ovale (PFO) closure for cryptogenic stroke points to a very low rate of ischemic events and no device safety issues emerging beyond 10 ...

It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...

PFO can in many cases be considered an anatomical variant. Patients with a PFO and without CS should be reassured that no further exams are necessary. The relationship between CS and PFO is known but ...

Shown are Kaplan–Meier estimates in the intention-to-treat population. The inset shows the same data on an enlarged y axis. The incidence of serious adverse events was similar in the two trial groups, ...

Researchers found closure of patent foramen ovale could result in reduced monthly migraine days. Treatment with patent foramen ovale (PFO) closure could reduce the frequency of headaches and monthly ...